Pantop%2525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the $H^+/K^+$-ATPase enzyme system at the secretory surface of the gastric parietal cell. ## Primary Indications * Short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Prophylaxis of stress-induced upper GI tract mucosal injury (off-label). ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. * **Hypersecretory Conditions:** Starting dose 40 mg IV or orally twice daily. Doses up to 240 mg/day have been used; adjust based on acid output. * **Stress Ulcer Prophylaxis:** 40 mg IV daily. ## Pediatric Dosing * **GERD (5 years and older):** * 15 kg to < 40 kg: 20 mg once daily. * 40 kg or greater: 40 mg once daily. * *Note: Duration of treatment should not exceed 8 weeks.* ## Dose Adjustments * **Renal Impairment:** No dosage adjustment necessary. * **Hepatic Impairment:** No specific adjustment required, but consider dose reduction in severe impairment due to potential for accumulation. ## Contraindications * Hypersensitivity to pantoprazole or any component of the formulation. * Concomitant use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous/systemic lupus erythematosus. ## Key Drug Interactions * **pH-dependent drugs:** May decrease the absorption of drugs requiring acidic environments (e.g., atazanavir, ketoconazole, iron salts, mycophenolate mofetil). * **Methotrexate:** May increase serum levels of methotrexate (monitor closely in high-dose therapy). * **Warfarin:** Monitor INR/PT due to potential changes in metabolism. ## Monitoring * Monitor for signs of *C. difficile* infection (worsening diarrhea). * Monitor magnesium levels if therapy exceeds 1 year or if used with drugs like diuretics. * Assess for clinical response to avoid inappropriate long-term use. ## Clinical Pearls * **Administration:** IV pantoprazole should be administered as a 15-minute infusion or a 2-minute slow injection. * **Transitioning:** Convert from IV to oral therapy as soon as the patient can tolerate oral intake. * **Deprescribing:** Utilize "tapering" strategies for patients on long-term therapy to mitigate rebound hypersecretion upon discontinuation. * **Proton Pump Inhibitors:** Should be used at the lowest effective dose for the shortest duration necessary. *** **Educational Disclaimer:** This information is for educational purposes only. Always consult current institutional protocols, package inserts, and evidence-based clinical databases (e.g., Lexicomp, Clinical Pharmacology) before prescribing or administering medication.